{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:00:17Z","timestamp":1793170817891,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["arthroplastytoday.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arthroplasty Today"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.artd.2026.102043","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:48:49Z","timestamp":1778935729000},"page":"102043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Glucagon-Like Peptide-1 Receptor Agonists in Hip and Knee Arthroplasty: A Comprehensive Systematic Review and Meta-Analysis of Perioperative and Postoperative Outcomes"],"prefix":"10.1016","volume":"39","author":[{"given":"Benjamin","family":"Wajda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Van Essen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golpira Elmi","family":"Assadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajrishi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Werle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.artd.2026.102043_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.artd.2024.101327","article-title":"K. Glucagon-like peptide receptor-1 agonists used for medically supervised weight loss in patients with hip and knee osteoarthritis","volume":"27","author":"Heckmann","year":"2024","journal-title":"Arthroplast Today"},{"key":"10.1016\/j.artd.2026.102043_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/oxfordjournals.aje.a114939","article-title":"Factors associated with osteoarthritis of the knee in the first National Health and Nutrition Examination Survey (HANES I)","volume":"128","author":"Anderson","year":"1988","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.artd.2026.102043_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s42836-022-00140-9","article-title":"Trends of obesity rates between primary total hip arthroplasty patients and the general population from 2013 to 2020","volume":"4","author":"Muthusamy","year":"2022","journal-title":"Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.arth.2022.03.003","article-title":"Projected prevalence of obesity in primary total knee arthroplasty: how big will the problem get?","volume":"37","author":"Carender","year":"2022","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2106\/JBJS.17.00120","article-title":"Risk reduction compared with access to care: quantifying the trade-off of enforcing a body mass index eligibility criterion for joint replacement","volume":"100","author":"Giori","year":"2018","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.artd.2026.102043_bib6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1017\/ice.2019.165","article-title":"The effect of body mass index on the risk of surgical site infection","volume":"40","author":"Meijs","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.artd.2026.102043_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcot.2022.101987","article-title":"The impact of obesity on total knee arthroplasty outcomes: a retrospective matched cohort study","volume":"33","author":"Aggarwal","year":"2022","journal-title":"J Clin Orthop Trauma"},{"key":"10.1016\/j.artd.2026.102043_bib8","article-title":"Impact of obesity on joint replacement surgery outcomes","volume":"17","author":"Rahman","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.artd.2026.102043_bib9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jama.2024.10816","article-title":"Medications for obesity: a review","volume":"332","author":"Gudzune","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.artd.2026.102043_bib10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40265-021-01525-x","article-title":"Is it time to expand glucagon-like peptide-1 receptor agonist use for weight loss in patients without diabetes?","volume":"81","author":"Updike","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.artd.2026.102043_bib11","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.artd.2026.102043_bib12","volume":"537","year":"2025"},{"key":"10.1016\/j.artd.2026.102043_bib13","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"key":"10.1016\/j.artd.2026.102043_bib14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.artd.2026.102043_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.artd.2026.102043_bib16","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgag052","article-title":"Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures","author":"Liu","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.artd.2026.102043_bib17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00592-025-02468-5","article-title":"Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis","volume":"62","author":"Tan","year":"2025","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.artd.2026.102043_bib18","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.artd.2026.102043_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"Plos Med"},{"key":"10.1016\/j.artd.2026.102043_bib20","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1016\/j.arth.2024.05.079","article-title":"Decreased risk of readmission and complications with preoperative GLP-1 analog use in primary total joint arthroplasty","volume":"39","author":"Buddhiraju","year":"2024","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.artd.2024.101506","article-title":"GLP-1 receptor agonist use is not associated with increased complications after total knee arthroplasty","volume":"30","author":"Heo","year":"2024","journal-title":"Arthroplast Today"},{"key":"10.1016\/j.artd.2026.102043_bib22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.arth.2024.10.099","article-title":"GLP-1 receptor agonist use is not associated with increased complications after total hip arthroplasty","volume":"40","author":"Heo","year":"2025","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib23","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.arth.2025.02.042","article-title":"Trends, demographics, and outcomes for glucagon-like Peptide-1 receptor agonist use in total knee arthroplasty: an 11-Year perspective","volume":"40","author":"Katzman","year":"2025","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2106\/JBJS.24.00468","article-title":"GLP-1 receptor agonists decrease complications in morbidly obese patients undergoing primary TKA","volume":"107","author":"Kim","year":"2025","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.artd.2026.102043_bib25","first-page":"1","article-title":"Utilization of GLP-1 receptor agonists at the time of total hip arthroplasty in patients with morbid obesity","volume":"39","author":"Kim","year":"2024","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib26","first-page":"1","article-title":"Effects of GLP-1 agonist therapy on infection, fracture, and revision after total joint arthroplasty","volume":"00","author":"Levidy","year":"2025","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.artd.2026.102043_bib27","doi-asserted-by":"crossref","DOI":"10.5435\/JAAOSGlobal-D-24-00148","article-title":"GLP-1 agonists in total hip arthroplasty: complications, readmissions, and patient-reported outcomes","volume":"8","author":"Magaldi","year":"2024","journal-title":"JAAOS Glob Res Rev"},{"key":"10.1016\/j.artd.2026.102043_bib28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.arth.2023.12.023","article-title":"Semaglutide use prior to total hip arthroplasty and postoperative outcomes","volume":"39","author":"Magruder","year":"2024","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib29","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.arth.2023.05.071","article-title":"Semaglutide use and outcomes following total knee arthroplasty","volume":"38","author":"Magruder","year":"2023","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.knee.2025.08.007","article-title":"GLP-1 agonists and postoperative outcomes following total knee arthroplasty","volume":"57","author":"Ranson","year":"2025","journal-title":"Knee"},{"key":"10.1016\/j.artd.2026.102043_bib31","first-page":"1","article-title":"Preoperative semaglutide exposure and outcomes after total knee arthroplasty","volume":"40","author":"Seddio","year":"2025","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib32","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.arth.2025.03.012","article-title":"GLP-1 agonists for weight loss: do they increase complications in non-diabetic patients undergoing primary total hip arthroplasty?","volume":"40","author":"Verhey","year":"2025","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib33","article-title":"PRISMA2020: an R package and shiny app for systematic reviews","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"key":"10.1016\/j.artd.2026.102043_bib34","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies","author":"Wells","year":"2000"},{"key":"10.1016\/j.artd.2026.102043_bib35","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.artd.2026.102043_bib36","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.3390\/ijms23073451","article-title":"GLP-1 receptor agonists in type 2 diabetes and obesity","volume":"23","author":"Klen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.artd.2026.102043_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"Anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.artd.2026.102043_bib38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","article-title":"Anti-inflammatory properties of GLP-1 receptor agonists","volume":"103","author":"Ros-Madrid","year":"2025","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.artd.2026.102043_bib39","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/j.arth.2017.04.065","article-title":"Hemoglobin A1c threshold for adverse outcomes after total joint arthroplasty","volume":"32","author":"Tarabichi","year":"2017","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib40","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.arth.2025.01.004","article-title":"Limited utility of hemoglobin A1c for predicting periprosthetic joint infection","volume":"40","author":"Palmer","year":"2025","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib41","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008805","article-title":"Hemoglobin A1c and periprosthetic joint infection: a systematic review and meta-analysis","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.artd.2026.102043_bib42","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(24)00163-3","article-title":"Bone health in adults with obesity before and after weight loss interventions","volume":"12","author":"Paccou","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.artd.2026.102043_bib43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00592-025-02468-5","article-title":"Effects of GLP-1 receptor agonists on bone outcomes in type 2 diabetes","volume":"62","author":"Tan","year":"2025","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.artd.2026.102043_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117338","article-title":"GLP-1 receptor agonists and fracture risk in type 2 diabetes","volume":"192","author":"Zhang","year":"2025","journal-title":"Bone"},{"key":"10.1016\/j.artd.2026.102043_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3168","article-title":"GLP-1 receptor agonists and fracture risk in type 2 diabetes","volume":"35","author":"Cheng","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.artd.2026.102043_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.arth.2025.07.015","article-title":"GLP-1 receptor agonists and outcomes after hip and knee arthroplasty: a systematic review and meta-analysis","author":"Lee","year":"2025","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.artd.2026.102043_bib47","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s00198-018-4649-8","article-title":"GLP-1 receptor agonists and fracture risk: a network meta-analysis","volume":"29","author":"Zhang","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.artd.2026.102043_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.61200","article-title":"Postoperative weight loss after anti-obesity medications and revision risk after joint replacement","volume":"8","author":"Xie","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Arthroplasty Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352344126000920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352344126000920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:22:40Z","timestamp":1782501760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352344126000920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":48,"alternative-id":["S2352344126000920"],"URL":"https:\/\/doi.org\/10.1016\/j.artd.2026.102043","relation":{},"ISSN":["2352-3441"],"issn-type":[{"value":"2352-3441","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide-1 Receptor Agonists in Hip and Knee Arthroplasty: A Comprehensive Systematic Review and Meta-Analysis of Perioperative and Postoperative Outcomes","name":"articletitle","label":"Article Title"},{"value":"Arthroplasty Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.artd.2026.102043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons.","name":"copyright","label":"Copyright"}],"article-number":"102043"}}